Neuvivo
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
530 Lytton Ave Fl 2214, Palo Alto, Calif...Phone Number
(650) 440-6766Website
www.neuvivo.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Neuvivo
About Neuvivo: Neuvivo is a private, late-clinical stage biopharmaceutical company committed to creating and delivering advanced treatments for ALS and other neurodegenerative diseases. The company was formed by industry leaders and scientists, committed to improving the prognosis for patients diagnosed with ALS and a range of diseases for which few current treatment options exist.Explore more
Neuvivo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuvivo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Neuvivo, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Neuvivo
Funding: Get notified immidiatlly once Neuvivo has new funding data
Check if Neuvivo has recently received funding, and reach out quickly before it becomes old news!
Check out if Neuvivo is spiking on competitors!
Product Launch: Get notified when Neuvivo launches new products
Click to see if Neuvivo had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Neuvivo recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Neuvivo
Compare insights from companies similar to Neuvivo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neuvivo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuvivo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuvivo.
Neuvivo financials insights
Gather financial insights about Neuvivo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$11M
Neuvivo Tech Stack
A closer look at the technologies used by Neuvivo
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Funding
Funding
Neuvivo News & Media
Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA
PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a pioneering company in biopharmaceutical innovation, is excited to announce the expansion of its Board of Directors with the appointment of Dr. Robert Baffi, PhD, MBA, a seasoned leader in the industry. This strategic addition underscores Neuvivo’s commitment to advancing its mission and driving growth. Dr. Baffi brings over 30 years of extensive experience in the biopharmaceutical sector, having held key leadership positions at renowned companies sSignificant Breakthroughs in Preserving ALS Lung Function and Survival Unveiled in Peer-Reviewed Studies of Novel Immunotherapy Platform NP001
PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational immunotherapy platform, NP001. The Overall Survival study demonstrated substantially extended survival in people living with ALS who received the investigational treatment. The second analysis identified the importance of underlying inflammation and the use of practical biomarkers to predict greater responsesNeuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment NP001
PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion) to treat amyotrophic lateral sclerosis (ALS). NP001 is an investigational treatment that, if approved, could be the first disease-modifying therapy for ALS that restores balance over uncontrolled inflammation within the body’s own innate immune system. The NP001Neuvivo Announces Mark Henderson, PhD, as Vice President of Manufacturing to Support Technical Operations for Investigational ALS Treatment
PALO ALTO, Calif. , Aug. 22, 2024 /PRNewswire/ -- Neuvivo, a biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Mark Henderson, PhD, as the company's new Vice...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuvivo
Sign Up For FreeTo access detailed company insights
About Neuvivo: Neuvivo is a private, late-clinical stage biopharmaceutical company committed to creating and delivering advanced treatments for ALS and other neurodegenerative diseases. The company was formed by industry leaders and scientists, committed to improving the prognosis for patients diagnosed with ALS and a range of diseases for which fe... Read More
